Crizotinib was the first ALK-TKI approved by the FDA in 2011, leading to a shift in first-line therapy option was changed from pemetrexed-plus-platinum to crizotinib for the ALK-positive NSCLC (Malik et al., 2014; Solomon et al., 2014). This evidence concerns the gene ALK and non-small cell lung carcinoma.